



## HUTCHMED (China) Limited

和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

### Annual General Meeting held on May 13, 2025

#### Poll Results

HUTCHMED (China) Limited ("[HUTCHMED](#)" or the "Company") today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on May 13, 2025 were duly passed. The poll results of the resolutions were as follows:

Ordinary Resolutions		Number of Votes (%)*			Passed by Shareholders
		For	Against	Withheld#	
1.	To consider and adopt the audited Financial Statements, and the Reports of the Directors and the Independent Auditors for the year ended December 31, 2024.	493,635,784 (99.9863%)	67,770 (0.0137%)	54,915	Yes
2(A).	To re-elect Dr Dan ELDAR as a Director.	479,808,571 (97.1824%)	13,910,941 (2.8176%)	38,955	Yes
2(B).	To re-elect Dr Weiguo SU as a Director.	481,283,821 (97.4806%)	12,438,811 (2.5194%)	35,835	Yes
2(C).	To re-elect Mr CHENG Chig Fung, Johnny as a Director.	481,167,431 (97.4570%)	12,555,206 (2.5430%)	35,830	Yes
2(D).	To re-elect Ms Edith SHIH as a Director.	466,597,573 (94.5061%)	27,124,459 (5.4939%)	35,935	Yes
2(E).	To re-elect Ms Ling YANG as a Director.	484,362,585 (98.1042%)	9,360,052 (1.8958%)	35,830	Yes
2(F).	To re-elect Dr Renu BHATIA as a Director.	493,441,294 (99.9430%)	281,240 (0.0570%)	35,935	Yes
2(G).	To re-elect Dr Chaohong HU as a Director.	493,441,904 (99.9431%)	280,740 (0.0569%)	35,825	Yes

Ordinary Resolutions		Number of Votes (%) <sup>*</sup>			Passed by Shareholders
		For	Against	Withheld <sup>#</sup>	
2(H).	To re-elect Professor MOK Shu Kam, Tony as a Director.	492,694,533 (99.7918%)	1,028,006 (0.2082%)	35,930	Yes
2(I).	To re-elect Mr WONG Tak Wai as a Director.	493,633,871 (99.9820%)	88,768 (0.0180%)	35,830	Yes
3.	To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as the Auditors of the Company for Hong Kong financial reporting and US financial reporting purposes, respectively, and to authorize the Directors to fix the Auditors' remuneration.	492,729,314 (99.8004%)	985,390 (0.1996%)	43,765	Yes
<b>Special Resolution</b>					
4.	To grant a general mandate to the Directors to issue additional shares of the Company. <sup>^</sup>	493,550,312 (99.9637%)	179,327 (0.0363%)	28,830	Yes
<b>Ordinary Resolution</b>					
5.	To grant a general mandate to the Directors to repurchase shares of the Company. <sup>^</sup>	493,321,158 (99.9180%)	405,036 (0.0820%)	32,275	Yes

<sup>\*</sup> Percentages rounded to 4 decimal places.

<sup>#</sup> A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a resolution.

<sup>^</sup> The full text of Resolutions 4 and 5 are set out in the notice of AGM dated April 8, 2025.

Notes:

- (1) All directors of the Company, namely Dr Dan ELDAR, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Ms Ling YANG, Mr Paul Rutherford CARTER, Dr Renu BHATIA, Dr Chaohong HU, Mr Graeme Allan JACK, Professor MOK Shu Kam, Tony and Mr WONG Tak Wai, attended the AGM, either in person or by means of electronic facilities.
- (2) Number of shares entitling the holders to attend and vote on the resolution at the AGM: 871,601,095 shares.
- (3) Number of shares entitling the holders to attend and abstain from voting in favor as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") at the AGM: Nil.
- (4) Number of shares for holders required under the Listing Rules to abstain from voting at the AGM: Nil.
- (5) The scrutineer for the poll at the AGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company.

## About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: [www.hutch-med.com](http://www.hutch-med.com) or follow us on [LinkedIn](#).

By Order of the Board

### Edith Shih

*Non-executive Director and Company Secretary*

Hong Kong, May 13, 2025

As at the date of this announcement following the conclusion of the AGM, the Directors of the Company are:

#### Chairman and Non-executive Director:

Dr Dan ELDAR

#### Executive Directors:

Dr Weiguo SU

*(Chief Executive Officer and  
Chief Scientific Officer)*

Mr CHENG Chi Fung, Johnny

*(Chief Financial Officer)*

#### Non-executive Directors:

Ms Edith SHIH

Ms Ling YANG

#### Independent Non-executive Directors:

Professor MOK Shu Kam, Tony

*(Senior and Lead Independent  
Non-executive Director)*

Dr Renu BHATIA

Dr Chaohong HU

Mr WONG Tak Wai